Bisphosphonates' use in metastatic bone disease.
Bisphosphonates already have an established role in the management of the skeletal complications of metastatic bone disease. The development of new, highly potent compounds has led to investigation into their use as preventive agents in the adjuvant setting. The aim of the paper is to evaluate the evidence for their use in prevention and treatment.
Hubner
R A
RA
St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford.
Houston
S J
SJ
D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D004164:Diphosphonates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology; D008297:Male; D023421:Models, Animal; D009101:Multiple Myeloma / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy
D004164:Diphosphonates